Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity.

Perry CJ, Muñoz-Rojas AR, Meeth KM, Kellman LN, Amezquita RA, Thakral D, Du VY, Wang JX, Damsky W, Kuhlmann AL, Sher JW, Bosenberg M, Miller-Jensen K, Kaech SM.

J Exp Med. 2018 Mar 5;215(3):877-893. doi: 10.1084/jem.20171435. Epub 2018 Feb 7.

2.

Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma.

Ngiow SF, Meeth KM, Stannard K, Barkauskas DS, Bollag G, Bosenberg M, Smyth MJ.

Oncoimmunology. 2015 Dec 10;5(3):e1089381. eCollection 2016 Mar.

3.

BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume.

Theodosakis N, Held MA, Marzuka-Alcala A, Meeth KM, Micevic G, Long GV, Scolyer RA, Stern DF, Bosenberg MW.

Mol Cancer Ther. 2015 Jul;14(7):1680-92. doi: 10.1158/1535-7163.MCT-15-0080. Epub 2015 May 6.

4.

Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.

Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, Kaech SM.

Cancer Res. 2014 Jun 15;74(12):3205-17. doi: 10.1158/0008-5472.CAN-13-3461. Epub 2014 Apr 15.

Supplemental Content

Loading ...
Support Center